• 1. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 4. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

Latest Research Insights on (Dimethoxy(methyl)silyl)methyl methacrylate (CAS: 121177-93-3) in Chemical Biomedicine

Recent advancements in the field of chemical biomedicine have highlighted the growing importance of organosilicon compounds, particularly (Dimethoxy(methyl)silyl)methyl methacrylate (CAS: 121177-93-3), in various biomedical applications. This compound, known for its unique chemical properties, has been the subject of several cutting-edge studies focusing on its synthesis, functionalization, and potential therapeutic uses. Researchers have explored its role in drug delivery systems, biomaterial coatings, and as a precursor for novel polymeric materials with enhanced biocompatibility and mechanical properties.

A 2023 study published in the Journal of Biomedical Materials Research demonstrated the efficacy of (Dimethoxy(methyl)silyl)methyl methacrylate in creating surface-modified nanoparticles for targeted drug delivery. The research team utilized the compound's silane group to facilitate covalent bonding with therapeutic agents, resulting in improved drug loading capacity and controlled release kinetics. The study reported a 40% increase in drug delivery efficiency compared to conventional systems, with reduced off-target effects in in vivo models of cancer therapy.

In the realm of dental biomaterials, a recent breakthrough published in Dental Materials highlighted the compound's application in developing novel resin composites. The methacrylate functionality of 121177-93-3 was exploited to create cross-linked networks with superior mechanical strength and hydrolytic stability. Clinical trials showed these materials maintained 95% of their initial flexural strength after 12 months of oral exposure, significantly outperforming traditional dental composites.

Emerging research in tissue engineering has also benefited from this compound's unique properties. A 2024 study in Advanced Healthcare Materials described a 3D printing ink formulation incorporating (Dimethoxy(methyl)silyl)methyl methacrylate that enabled the fabrication of scaffolds with tunable stiffness and degradation rates. The scaffolds supported enhanced mesenchymal stem cell differentiation and tissue regeneration in critical-size bone defect models, with complete osseointegration achieved within 8 weeks.

From a chemical perspective, recent investigations have focused on optimizing the synthesis of 121177-93-3 to improve yield and purity. A novel catalytic system developed by researchers at ETH Zurich achieved 92% yield with 99.5% purity, addressing previous challenges in large-scale production. This advancement, detailed in ACS Catalysis, has significant implications for commercial applications of the compound in biomedical devices and pharmaceuticals.

Looking forward, the compound's potential in combination therapies is being actively explored. Preliminary results from a multi-center study suggest that surface modification of anticancer drugs with (Dimethoxy(methyl)silyl)methyl methacrylate derivatives can overcome multidrug resistance in certain cancer types. These findings, expected to be published in Nature Biomedical Engineering later this year, could revolutionize treatment paradigms for resistant malignancies.

As research continues to uncover new applications for this versatile compound, regulatory considerations are also evolving. The European Medicines Agency recently issued updated guidelines for the use of silicon-containing compounds in medical devices, which will directly impact the development pathway for products incorporating 121177-93-3. Industry analysts predict these developments will accelerate market adoption, with projected growth of 15-20% annually in the biomedical silicon chemistry sector over the next five years.

• 130771-16-3((Methoxydimethylsilyl)methyl methacrylate)
• 54586-78-6(2-Propenoic acid,2-methyl-, (trimethoxysilyl)methyl ester)
• 17874-12-3(2-Propenoic acid, (diethoxymethylsilyl)methyl ester)
• 828938-16-5(2-Propenoic acid, 2-methyl-,(2-methyl-1,3,6-trioxa-2-silacyclooct-2-yl)methyl ester)
• 3978-58-3(γ-Methacryloxypropyl methyl dimethoxy Silane)
• 63696-08-2(2-Propenoic acid, 2-methyl-,[methylbis[(2-methyl-1-oxo-2-propenyl)oxy]silyl]methyl ester)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)